Want to see HK:2137 full AI Analyst Report?
Top Page
Brii Biosciences Limited
(2137)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$0.91
▼(-36.74% Downside)
Action:Reiterated
Date:07/04/26
The score is held down primarily by weak financial performance (ongoing losses, negative margins, and continued cash burn despite some 2025 improvement) and bearish technical signals (negative MACD and trading below key longer-term moving averages). A strong, low-debt balance sheet provides some support, but valuation is not compelling given the negative P/E and lack of dividend yield.
Positive Factors
Low leverage and positive equity
Very low leverage and sustained positive equity provide a meaningful financial cushion while the company funds development and commercialization. This reduces balance-sheet risk, preserves flexibility for partnerships or investment, and offers greater resilience than a highly indebted biotechnology model during extended development cycles.
Negative Factors
Persistent losses and negative margins
Continued losses and deeply negative margins show that the operating model has not yet reached sustainable profitability. This limits internally generated funding, leaves earnings dependent on future product execution, and makes the business more vulnerable to setbacks in development, approvals, or commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and positive equity
Very low leverage and sustained positive equity provide a meaningful financial cushion while the company funds development and commercialization. This reduces balance-sheet risk, preserves flexibility for partnerships or investment, and offers greater resilience than a highly indebted biotechnology model during extended development cycles.
Read all positive factors
Brii Biosciences Limited (2137) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$671.68M
Dividend YieldN/A
Average Volume (3M)802.26K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue GrowthN/A
EPS Growth51.71%
CountryHK
Employees80
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding734,958,250
10 Day Avg. Volume1,026,500
30 Day Avg. Volume802,259
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.43
Revenue Forecast (FY)N/A
Brii Biosciences Limited Business Overview & Revenue Model
Company Description
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: earl...
How the Company Makes Money
Brii Biosciences makes money primarily through (1) commercialization revenue from products it markets/sells (where applicable), and (2) collaboration- and licensing-related income tied to partnered assets. Commercialization revenue generally comes...
Brii Biosciences Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.29M | 18.12M | 54.29M | 56.32M | 51.63M | 92.54M |
| Gross Profit | 11.54M | 0.00 | 54.29M | 56.32M | 51.63M | 92.54M |
| EBITDA | -262.17M | -290.29M | -392.51M | -168.20M | -503.58M | -602.80M |
| Net Income | -167.97M | -216.86M | -508.16M | -174.83M | -484.31M | -4.12B |
Balance Sheet | ||||||
| Total Assets | 2.20B | 2.36B | 2.71B | 3.20B | 3.39B | 3.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.77B | 1.94B | 2.33B | 2.66B | 3.00B | 3.35B |
| Total Debt | 6.18M | 8.93M | 28.02M | 3.16M | 12.66M | 21.62M |
| Total Liabilities | 36.36M | 36.22M | 100.55M | 125.87M | 234.35M | 300.44M |
| Stockholders Equity | 2.22B | 2.38B | 2.66B | 3.12B | 3.19B | 3.34B |
Cash Flow | ||||||
| Free Cash Flow | -105.69M | -288.42M | -376.12M | -643.62M | -635.57M | -880.49M |
| Operating Cash Flow | -103.83M | -286.55M | -372.89M | -594.01M | -496.28M | -879.46M |
| Investing Cash Flow | -845.55M | -151.31M | 895.47M | -104.35M | -1.43B | -475.76M |
| Financing Cash Flow | -20.84M | -39.12M | -9.41M | -10.98M | -3.04M | 3.23B |
Brii Biosciences Limited Technical Analysis
Negative
1.44
Price Trends
0.99
Negative
1.10
Negative
1.32
Negative
Market Momentum
-0.02
Positive
42.48
Neutral
15.03
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2137, the sentiment is Negative. The current price of 1.44 is above the 20-day moving average (MA) of 0.97, above the 50-day MA of 0.99, and above the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.48 is Neutral, neither overbought nor oversold. The STOCH value of 15.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2137.
Brii Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$26.93B | 60.92 | 15.79% | ― | 48.04% | 166.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$1.84B | 27.96 | 48.25% | ― | 88.38% | ― | |
50 Neutral | HK$2.73B | 2.72 | -64.89% | ― | -99.15% | ― | |
46 Neutral | HK$671.68M | -3.33 | -7.32% | ― | ― | 51.71% | |
45 Neutral | HK$456.37M | -1.82 | -32.08% | ― | 215.14% | 40.49% | |
44 Neutral | HK$2.29B | -2.98 | -24.66% | ― | -18.45% | -151.15% |
* Healthcare Sector Average
HK:2137
Brii Biosciences Limited
0.93
-1.30
-58.30%
HK:2181
Mabpharm Limited
0.45
-0.34
-42.95%
HK:2197
Clover Biopharmaceuticals Ltd.
2.10
0.17
8.81%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
60.60
34.76
134.52%
HK:6628
Transcenta Holding Limited
1.03
-4.15
-80.21%
HK:6660
AIM Vaccine Co., Ltd. Class H
1.87
-3.22
-63.36%
Brii Biosciences Limited Corporate Events
Brii Biosciences Narrows Interim Loss as HBV and RNA Pipelines Advance
Aug 20, 2026
Brii Biosciences Limited reported unaudited interim results for the six months ended June 30, 2026, showing cash and bank deposits of RMB1.77 billion, down 8.8% mainly due to research and development spending and operating costs. The company narro...
Brii Biosciences Sets August Board Meeting to Approve 2026 Interim Results
Aug 7, 2026
Brii Biosciences Limited has announced that its board of directors will convene on August 20, 2026, to review and approve the unaudited interim results for the six months ended June 30, 2026. The meeting will also address the publication of these ...
Brii Biosciences Posts Promising Phase 2b Hepatitis B Data but Elebsiran Future Clouded by Arbitration
Jul 2, 2026
Brii Biosciences has reported end-of-treatment data from its Phase 2b ENRICH and ENHANCE studies evaluating different combination regimens of BRII-179, elebsiran and PEG-IFN α for chronic hepatitis B. The ENRICH trial, which uses BRII-179 as ...
Brii Biosciences Launches HK$60 Million Share Buy-back to Signal Confidence and Unlock Value
Jun 17, 2026
Brii Biosciences Limited has announced that its board plans to use an existing shareholder mandate to repurchase up to 10% of its issued shares, excluding treasury shares, via an on-market buy-back programme. The company has capped the total funds...
Brii Biosciences Shareholders Approve All Resolutions at 2026 AGM
Jun 16, 2026
Brii Biosciences reported that all resolutions proposed at its 2026 annual general meeting, held in Hong Kong on June 16, were approved by shareholders via poll, including the adoption of the audited consolidated financial statements and related d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.